A comprehensive analysis published in Reserch illuminates how cancer cells hijack immune checkpoints on natural killer (NK) cells to disable the body’s frontline defense system. The study details: ...
Vaxiion Therapeutics Announces Completion of Phase 1a Dose Escalation and Initiation of a Phase 1b Dose Expansion Study for Intralesional Administration of VAX014 in Combination with PD-1 Directed ...
Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint blockade for treatment of non-small cell lung cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback